NCT03755440View on ClinicalTrials.gov

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Gastric Cancer Stage IVEBV
Interventions
DRUG

PD-1 antibody (SHR-1210)

PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.

Trial Locations (1)

510060

Cancer center of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03755440 - PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | Biotech Hunter | Biotech Hunter